On Wednesday, the mid-cap company’s share price increased by 12% to an intraday high of Rs 1,935 per share, up from its previous close of Rs 1,724 following the company’s December results and investor presentation.
According to the exchange filing, J B Chemicals & Pharmaceuticals Ltd has announced its quarterly result for December, interim dividend, and its business update for Q3.
Looking at their financials, the net revenue of the company rose by 6.5% YoY from Rs 793 crore in Q3FY23 to Rs 845 crores in Q3FY24 on a sequential basis their net revenue fell by 4% from Rs 882 crore in Q2FY24 to its current level.
The net profit of the company rose by 26% YoY from Rs 106 crore in Q3FY23 to Rs 134 crore in Q3FY24 on a sequential basis; their net profit rose by 11% from Rs 151 crore in Q2FY24 to its current level.
Additionally, in their business highlights, JB Pharma’s Q3 FY24 revenue grew 7% to INR 845 crores, driven by domestic formulations’ 14% increase. Excluding South Africa, international revenue rose 10%. Operating EBITDA surged 22%, with margins improving by 350 bps.
Domestic revenue reached Rs 462 crores, up 14%, while international revenue, excluding South Africa, showed single-digit growth.
The company has a market capitalization of Rs 27,990, J B Chemicals & Pharmaceuticals Ltd has a low debt-to-equity ratio of 0.23, and their share price rose by 78% in the last year.
J.B. Chemicals and Pharmaceuticals Limited, founded in 1976, is one of India’s most prominent pharmaceutical companies. JBCPL is a publicly traded, integrated organization that focuses on providing affordable, high-quality products in India and around the world. Healthcare professionals worldwide rely on JBCPL.
Written by Sriram KV
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
